Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 6;96(14):e1876-e1886.
doi: 10.1212/WNL.0000000000011703. Epub 2021 Feb 16.

Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study

Jeffrey A Allen  1 , Mamatha Pasnoor  2 , Mazen M Dimachkie  2 , Senda Ajroud-Driss  2 , Thomas H Brannagan  2 , Albert A Cook  2 , Timothy Walton  2 , Mark B Fiecas  2 , John T Kissel  2 , Ingemar Merkies  2 , Kenneth C Gorson  2 , Richard A Lewis  2
Affiliations
Observational Study

Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study

Jeffrey A Allen et al. Neurology. .

Abstract

Objective: The objective of this study was to explore the extent of IV immunoglobulin (IVIG) treatment-related fluctuations (TRFs) by using home collection of daily grip strength in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and to use that information to develop evidence-based treatment optimization strategies.

Methods: This prospective observational study included 25 patients with well-defined CIDP. Participants recorded grip strength daily for 6 months. Disability and gait metrics were collected weekly. Serum immunoglobulin G levels were obtained at peak, trough, and midcycle IVIG intervals. Day-to-day grip strength changes <10% were considered random. To identify patients with TRFs, 3-day averaged grip strength was calculated on each consecutive day after an IVIG infusion. TRFs were defined as ≥10% 3-day averaged grip strength difference compared to the pre-IVIG baseline.

Results: Participants successfully recorded grip strength on all but 9% of recordable days. Twelve patients (48%) were classified as low/no fluctuaters and 13 (52%) as frequent fluctuaters. In the frequent fluctuating group, grip strength improved over 1 week and thereafter was relatively stable until the third week after infusion. Grip strength was significantly correlated with measures of disability.

Conclusions: Grip strength collection by patients at home is reliable, valid, and feasible. A change in grip strength by ≥10% is a useful, practical, and evidence-based approach that may be used to identify clinically meaningful TRFs. From these data, we propose a treatment optimization strategy for patients with CIDP on chronic IVIG that may be applied to routine clinic care during both face-to-face and virtual video or telephone patient encounters.

Trial registration information: ClinicalTrials.gov Identifier: NCT02414490.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Correlation Between Grip Strength Collected by Patients and Nurses in Dominant and Nondominant Hands
Figure 2
Figure 2. Dominant and Nondominant Hand TRFs in 25 Patients
Treatment-related fluctuation (TRF) deterioration (white), TRF improvement (black), or no TRFs (gray) in patients receiving IV immunoglobulin (IVIG). D = dominant hand; N = nondominant hand. *Patients classified as frequent fluctuaters.
Figure 3
Figure 3. Percent Change in 3-Day Averaged Dominant and Nondominant (Combined) Hand Grip Strength
Grip strength across all patients and all cycles in participants with (A) frequent treatment-related fluctuations (TRFs) and (B) low or no TRFs.
Figure 4
Figure 4. Proposed Approach to IVIG Optimization for Patients With CIDP on Long-Term IVIG Therapy
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; GS = grip strength; IVIG = IV immunoglobulin; TRF = treatment-related fluctuation.
See this image and copyright information in PMC

References

    1. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. Eur J Neurol 2010;17:356–363. - PubMed
    1. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39:432–438. - PubMed
    1. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326–333. - PubMed
    1. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136–144. - PubMed
    1. Allen JA, Berger M, Querol L, Kuitwaard K, Hadden RD. Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies. J Peripher Nerv Syst 2018;23:78–87. - PMC - PubMed

Publication types

Substances

Associated data